Elise T. Wang

Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis.

Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL.

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

Deerfield Management Co. LP (Deerfield) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Peter Drake in 1994. They are wholly owned by James E. Flynn and are controlled by its general partner, Flynn Management LLC. Deerfield provides discretionary investment management services in the healthcare sector to domestic and offshore private pooled investment vehicles and their related alternative investment vehicles.

Jaguar Gene Therapy LLC is a clinical stage biotechnology company based in Lake Forest, IL. Jaguar Gene Therapy LLC is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company has a proven team of experts who have experience in bringing novel gene therapy treatments to patients and their families. Jaguar is rapidly advancing an initial pipeline of three programs, including targeting severe neurodevelopmental disorders, type 1 galactosemia, and type 1 diabetes. The company partner with Advanced Medicine Partners for manufacturing their therapeutics. Key investors include Deerfield Management Company, Arch Venture Partners, and Eli Lilly and Company. The company was founded by Daniel Gallo, and Joseph Nolan has been the CEO since 2020.